Guillain-Barre Syndrome Following Ad26.Cov2.S Covid-19 Vaccine: A Case Report

Authors

  • Sushmita Khanal Department of Intensive Care Unit, Department of Cardiology, Nobel Medical College Teaching Hospital, Biratnagar, Nepal https://orcid.org/0000-0001-8908-1887
  • Sunil Babu Khanal Department of Intensive Care Unit, Department of Cardiology, Nobel Medical College Teaching Hospital, Biratnagar, Nepal

DOI:

https://doi.org/10.3126/jonmc.v10i2.41790

Keywords:

COVID-19 Vaccines, Guillain-Barre Syndrome

Abstract

Guillain-Barre Syndrome has been reported as a rare side effect in the recipients of Johnson & Johnson®'s Janssen Ad26.COV2.S COVID-19 vaccine. We report a case of Guillain-Barre Syndrome in a 50 years old female following the administration of the aforementioned vaccine.

Downloads

Download data is not yet available.
Abstract
458
PDF
202

Author Biography

Sushmita Khanal, Department of Intensive Care Unit, Department of Cardiology, Nobel Medical College Teaching Hospital, Biratnagar, Nepal

Medical Officer

Cover JoNMC

Downloads

Published

2021-12-31

How to Cite

Khanal, S., & Khanal, S. B. (2021). Guillain-Barre Syndrome Following Ad26.Cov2.S Covid-19 Vaccine: A Case Report. Journal of Nobel Medical College, 10(2), 63–64. https://doi.org/10.3126/jonmc.v10i2.41790

Issue

Vol. 10 No. 2 (2021)

Section

Case Reports

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

JoNMC applies the Creative Commons Attribution (CC BY) license to works we publish. Under this license, authors retain ownership of the copyright for their content, but they allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited.